Weight Pills in 2026: Wegovy Tablets vs Foundayo by Country

People hear “weight loss pill” and think one product. Regulators do not. Wegovy tablets are oral semaglutide with fasting and water rules. Foundayo is oral orforglipron — a different molecule, different carton, different country map, and no fasting lock on the labels used here. Mixing them in your head — or treating a UK carton as an EU or Canadian care plan — is how people get the wrong script.

This episode is the oral maze: comparison + country matrix. Episode 1 covered injectable Wegovy only. Episode 2 covered Zepbound / tirzepatide weight and sleep apnea. The live Foundayo (orforglipron) article is the product deep dive — cross-link only; this episode does not rewrite its trial tables, interaction locks, or safety sections. Compounded or grey-market “GLP-1 pills” are not an Access Level door.

Where this is taking place

Commercial path: a prescriber writes the local labelled oral carton — Wegovy tablets and/or Foundayo where that country’s regulator has authorised them — a pharmacy dispenses a real manufacturer pack, and you take the tablet once daily with a reduced-calorie diet and more activity. This is not a trial slot, not a compounding bench, and not mail-ordering a neighbour’s bottle.

Key evidence programmes that sit under the labels (historical — not open enrolment doors for a first commercial script):

• Oral Wegovy weight (adults): OASIS programme — OASIS 4 / NCT05564117 supports the oral weight door used on US/EU materials.
• Foundayo weight (adults): ATTAIN-1 / NCT05869903 (without type 2 diabetes) and ATTAIN-2 / NCT05872620 (with type 2 diabetes) — full product dive on the live Foundayo piece.

Series map (brief, not rehash): Episode 1 = injectable Wegovy multi-door. Episode 2 = Zepbound weight/OSA (and the Mounjaro brand split). Live Foundayo = orforglipron product deep dive. Episode 4 owns reimbursement / prior auth / compounding as process.

The fasting vs anytime distinction (fact only)

These are administration and label facts, not a claim that one pill is “better,” easier, safer, or more effective. No direct head-to-head oral Wegovy–versus–Foundayo trial was verified for this draft. Switching between injections and tablets, or between brands, belongs to the local label and the clinician — not a reader tip.

Approval matrix (oral weight doors)

Use the label of the country that will prescribe. A US Foundayo weight-only line does not become a UK type 2 diabetes licence. A UK MHRA decision does not become an EU pack. A US or UK carton is not a Canadian care plan.

Access by country

• United States: Ask a clinician who manages obesity (and cardiology risk if the CV door fits) about labelled oral Wegovy and/or labelled Foundayo. Both are FDA-approved adult weight doors; oral Wegovy also carries the adult CV-risk-reduction door. Follow the fasting/water rules for Wegovy tablets or the with-or-without-food rule for Foundayo — they are not interchangeable habits. Do not combine either with another GLP-1 RA or another semaglutide product. Prior authorization is common. No public-funding win is claimed here. Novo Nordisk adverse events (Wegovy): 1-833-934-6891; Lilly (Foundayo): 1-800-545-5979; FDA MedWatch 1-800-FDA-1088.

• Canada (gap zoom, not a green light): Oral Wegovy NOC/DIN and Foundayo NOC/DIN are not confirmed on this page. CDA-AMC SR0955-000 for orforglipron is a reimbursement review filed Pre-NOC — that is not Health Canada authorisation and not a provincial listing. Injectable Wegovy and injectable Zepbound (Episodes 1–2) remain separate doors. Do not mail-order a US or UK oral bottle as a Canadian care plan. SAP is unknown for these non-marketed orals and is not presented here as a routine Access Level path.

• United Kingdom: Both orals are MHRA-authorised for adult weight management; Foundayo also carries a UK type 2 diabetes glycaemic-control line. GOV.UK is explicit for both: not currently available via the NHS; NICE evaluation follows established processes. Ask the specialist / private weight or diabetes team what is actually dispensable. Authorized ≠ NHS. Yellow Card for suspected side effects. Do not buy from unregulated sellers.

• EU/EEA: Oral Wegovy is Commission-authorised for adult weight management (15 Jul 2026 extension). Member-state supply and reimbursement remain country-specific — unknown here unless a country file is opened. Foundayo EU/EC authorisation: not confirmed. Do not DIY-import a UK Foundayo pack as an EU care plan.

• Australia: Oral registration for Wegovy tablets and Foundayo: not confirmed on this page. Injectable Wegovy and Rybelsus (diabetes tablets) are not answers to the oral Wegovy weight question. PBS unknown / not confirmed.

• If your regulator has not authorised the oral door you need: do not import on your own. Ask a local clinician about legal special-access / named-patient rules only if those programs apply — or wait for a local label. Episode 1’s injectable Wegovy or Episode 2’s tirzepatide door may still be the local commercial path.

What they actually are

Oral Wegovy is semaglutide, a GLP-1 receptor agonist, in a once-daily tablet co-formulated with an absorption enhancer (SNAC). It is used with diet and activity. On the US label, tablets cover adult weight and adult CV risk reduction — not the injection-only MASH door, and not a pediatric tablet door.

Foundayo is orforglipron, a small-molecule (non-peptide) GLP-1 receptor agonist, in a once-daily tablet. US label: adult weight only. UK label: adult weight plus type 2 diabetes glycaemic control. Full product, titration, CYP3A4 / simvastatin / oral-contraceptive locks: see the live Foundayo article.

Neither is:

• Injectable Wegovy (Episode 1 — weekly shot; different doors including teens 12+ weight and MASH where labelled)
• Rybelsus (oral semaglutide diabetes brand — different labelled door)
• Ozempic / Mounjaro / Zepbound (different brands / molecules / episodes)
• A UK licence travelling to the US, or a US bottle travelling to Canada
• An EMA-wide Foundayo door (not confirmed)
• Compounded / grey-market “semaglutide tablets” or “orforglipron”
• Public coverage just because a regulator said yes
• A head-to-head winner

US oral Wegovy escalation (adults): days 1–30: 1.5 mg; 31–60: 4 mg; 61–90: 9 mg; then maintenance 25 mg once daily. Missed tablet dose (USPI): skip and take the next dose the following day. Switching between Wegovy injection and tablets has labelled pathways — clinician-directed only.

US note on type 2 diabetes + oral Wegovy: the USPI states tablets have not been studied for weight reduction in adults with type 2 diabetes and obesity/overweight, and average blood levels after tablets may be lower in people with type 2 diabetes — some patients may get subtherapeutic exposure; the label points clinicians toward alternatives including switching to Wegovy injection. That is a US label fact, not a global tip sheet.

What the trials showed (plain numbers — separate programmes)

Oral Wegovy — OASIS 4 (NCT05564117; EMA overview / NEJM): In adults with obesity or overweight + comorbidity without diabetes, once-daily oral semaglutide 25 mg for ~64 weeks cut body weight on the order of ~14% vs about ~2% on placebo (NEJM treatment-policy estimate −13.6% vs −2.2%). Most people on drug lost at least 5% of body weight. Gastrointestinal side effects were the main tolerability story. This supports the oral weight door — it is not a head-to-head vs Foundayo.

Foundayo — ATTAIN-1 / ATTAIN-2: Week-72 weight reductions on the USPI tables (e.g. about −11% at 17.2 mg vs about −2% placebo without diabetes in Trial 1; somewhat less weight loss in the diabetes Trial 2 pattern) live on the Foundayo product article. This episode does not reprint those tables.

Separate programmes. Separate molecules. No winner narrative.

Safety a household should actually watch

Boxed / serious warning (US labels): Both products carry MTC/MEN2 contraindication language. Wegovy tablets use the familiar GLP-1 rodent C-cell tumour boxed warning. Foundayo’s USPI notes orforglipron was not pharmacologically active in rats/mice and did not produce rodent thyroid tumours — human relevance of rodent findings is still discussed in class language — and MTC/MEN2 remain contraindications. Do not use either oral if you or your family have medullary thyroid cancer (MTC) or MEN2.

Common (both oral GLP-1 class): nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, headache, fatigue — especially while doses climb.

Watch for and call urgently: severe persistent abdominal pain (pancreatitis), gallbladder pain, signs of severe allergic reaction, symptoms of low blood sugar if you also take insulin or a sulfonylurea, dehydration from vomiting/diarrhea (kidney injury risk), vision changes if you have diabetes and retinopathy history.

Oral-specific watchpoints:

• Wegovy tablets: delayed stomach emptying can affect other oral medicines — the 30-minute wait after the tablet matters; tell surgeons/anesthesia teams before procedures; breastfeeding not recommended on the US tablet label because of SNAC in milk (injection is a different conversation).
• Foundayo: CYP3A4 / simvastatin / oral-contraceptive timing locks — details on the live Foundayo piece; tell the surgical team before anesthesia.

Pregnancy: May cause fetal harm. For weight/CV use of Wegovy, stop when pregnancy is recognized; plan pregnancy by stopping at least 2 months ahead (long half-life). Foundayo: discontinue when pregnancy is recognized; registry contacts on the live article.

Teens: Oral Wegovy tablets and Foundayo are adult doors on the labels used here. Injectable Wegovy’s 12+ weight door is Episode 1 — do not copy it onto tablets.

Access: what you can actually do

1. Name the oral brand and the country

If the clinic says “I’ll just write a GLP-1 pill,” ask which labelled oral — Wegovy tablets or Foundayo — and whether that product is authorised where you will be prescribed. Fasting rules and indication lines are not the same.

2. Who to see

A clinician who already manages obesity (and diabetes or cardiology risk as fits): primary care, obesity medicine, or endocrinology. Bring: BMI, weight-related conditions, heart history if relevant, full med list (especially other GLP-1s, insulin, sulfonylureas, simvastatin / CYP3A4 drugs for Foundayo), gallbladder history, pregnancy plans, and whether injections are off the table for you and why.

3. Script for the visit

I am asking about a labelled oral weight medicine for this country — either Wegovy tablets (semaglutide; fasting and water rules) or Foundayo (orforglipron; with or without food), not compounded pills and not stacking with another GLP-1. On the US labels, both are adult weight doors; oral Wegovy also has a cardiovascular-risk-reduction door. The UK has authorised both orals for weight, and Foundayo also for type 2 diabetes there — but authorised is not NHS. Canada has not confirmed an oral NOC/DIN for either on the sources I have. I want to know which door exists here, whether you will prescribe the real carton, how the fasting vs anytime rules apply to my other medicines, and what the realistic payment path is. I understand authorized is not funded, and I am not asking you to declare one pill “better” without a comparative trial.

Ask:

• Which oral is authorised in this country for my situation?
• Am I outside the label (under 18; MEN2/MTC; pregnancy; already on another GLP-1)?
• Exact administration rules I must follow (fasting/water vs anytime)?
• Escalation plan and missed-dose rules?
• Insurance prior authorization language (Wegovy tablets / Foundayo / indication)?
• Surgery or procedures coming up?

4. Payment honesty

Authorized ≠ funded. US commercial prior auth is common for both. Canadian public listing for these orals is N/A until there is a NOC — and no oral NOC is confirmed here. UK: both orals not currently NHS per GOV.UK. EU national reimbursement and Australia PBS: unknown / not confirmed. Episode 4 covers reimbursement process across the series doors.

5. Compounded products are not this door

If a spa, med-spa, or online seller offers “semaglutide tablets,” “oral GLP-1,” or “orforglipron” without a labelled Wegovy or Foundayo carton, that is not the Access Level path this episode maps.

6. Clinical trials

OASIS and ATTAIN support labels; they are not a 2026 walk-in enrolment path for a first commercial bottle in countries where the product is already marketed. Search ClinicalTrials.gov with your clinician only if you need a research door your local label does not cover.

7. If you are not a candidate for either oral

Under 18 on these oral labels; personal/family MTC or MEN2; pregnancy; already on another GLP-1 you should not stack; or your country has not authorised either oral — ask about Episode 1 injectable Wegovy or Episode 2 tirzepatide where those are the local labelled doors. Do not substitute brands in your head, and do not import on your own.

---

Bottom line

Oral Wegovy and Foundayo are two real, distinct, labelled adult oral weight doors — fasting semaglutide tablet vs anytime orforglipron tablet. Both are FDA-approved. Oral Wegovy also carries a US heart-risk door and EU/UK adult weight authorisations. Foundayo’s UK authorisation (weight + type 2 diabetes) is a UK label, not an EMA-wide licence, and not currently NHS. Canada has no confirmed oral NOC/DIN for either product on this page. Neither pill is Episode 1’s weekly Wegovy shot. Neither is compounded. Neither is funded just because it is authorised. Ask for the labelled oral carton that matches your country’s matrix — then fight the payment step with eyes open.

---